Reposal
Chemical compound
- N05CA12 (WHO)
- 5-bicyclo[3.2.1]oct-2-en-3-yl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione
- 3625-25-0
N
- 19254
- 10468690
Y
- 3T5TIX1AYI
- ChEMBL505851 N
- DTXSID50877567
- Interactive image
- O=C1NC(=O)NC(=O)C1(CC)C=3C[C@H]2C[C@H](CC2)C=3
InChI
- InChI=1S/C14H18N2O3/c1-2-14(11(17)15-13(19)16-12(14)18)10-6-8-3-4-9(5-8)7-10/h6,8-9H,2-5,7H2,1H3,(H2,15,16,17,18,19)/t8-,9+/m0/s1Y
- Key:MKELYWOVSPVORM-DTWKUNHWSA-NY
N
Y (what is this?) (verify)Reposal is a barbiturate derivative invented in the 1960s in Denmark. It has sedative, hypnotic and anticonvulsant properties, and was used primarily for the treatment of insomnia.[1][2][3]
References
- ^ Kessing SV, Tarding F, Thomsen AC (December 1963). "Reposal, A New Hypnotic. I. Pharmacodynamic Activity". Ugeskrift for Laeger (in Danish). 125: 1735–8. PMID 14103836.
- ^ Kessing SV, Tarding F, Thomsen AC (December 1963). "Reposal, A New Hypnotic. Ii. Clinical Effects". Ugeskrift for Laeger (in Danish). 125: 1739–41. PMID 14103837.
- ^ Nielsen P, Tarding F (1968). "The metabolic fate of 5-(bicyclo-3,2,1,-oct-2-en-2-yl)-5-ethyl barbituric acid, (Reposal)". Acta Pharmacologica et Toxicologica. 26 (6): 521–30. doi:10.1111/j.1600-0773.1968.tb00471.x. PMID 5756387.
- v
- t
- e
Hypnotics/sedatives (N05C)
| Antihistamines | |
|---|---|
| Antidepressants | |
| Antipsychotics |
| Antidepressants | |
|---|---|
| Antipsychotics | |
| Others |
- Agomelatine
- Melatonin
- Ramelteon
- Tasimelteon
- Cannabidiol
- Cannabis
- Chlorophenylalkyldiols
- Diethylpropanediol
- Evoxine
- Fenadiazole
- Guaifenesin-related muscle relaxants
- Midaflur
- Opioids (e.g., morphine)
- Passion flower
- Scopolamine
- Trazodone
- UMB68
- Valnoctamide
 | This sedative-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
